Connect your AI

Veracyte VCYT Total Liabilities

Total Liabilities at other companies

Guardant HealthGH

$2.1B+31.4%

Natera, Inc.NTRA

$125.55M-74.5%

Bio-Rad LaboratoriesBIO

$2.94B+3.2%

RevvityRVTY

$4.81B+1.9%

Labcorp HoldingsLH

$10.34B+11.4%

Agilent TechnologiesA

$5.94B-1.3%

Other financials

Income statement

Revenue$139.1M+21.5%

Gross profit$101.2M+27.2%

Operating income$22.6M+680%

Net income$28.7M+307%

EPS (diluted)$0.35+289%

Balance sheet

Cash & equivalents$264.8M+41.0%

Total debt$39.3M-22.1%

Total equity$1.3B+12.5%

Total assets$1.4B+9.2%

Cash flow

Operating cash flow$35.2M+557%

CapEx$3.0M+62.8%

Free cash flow$32.3M+810%

Valuation

Market cap$4.29B+10.7%

Profitability

Gross margin70.9%+2.9pp

Operating margin14.3%+9.2pp

Net margin16.2%+9.1pp

FCF margin28.7%+11.7pp

Returns & leverage

Return on equity6.9%+4.1pp

Debt / equity0×0.0×

Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Veracyte's total liabilities?: Veracyte (VCYT) reported total liabilities of $91.99M in Q1 2026.
How has Veracyte's total liabilities changed year-over-year?: Veracyte's total liabilities decreased by 23.6% year-over-year, from $120.48M to $91.99M.
What is the long-term trend for Veracyte's total liabilities?: Over 5 years (2020 to 2025), Veracyte's total liabilities has grown at a 21.8% compound annual growth rate (CAGR), from $35.93M to $96.44M.
What does total liabilities mean?: The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.